Charles Zhu
Stock Analyst at Guggenheim
(2.43)
# 2,422
Out of 5,149 analysts
19
Total ratings
47.06%
Success rate
16.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $11.50 | +4.35% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $11.19 | +96.60% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.89 | +534.92% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $100.22 | -44.12% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $6.15 | +257.72% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $37.24 | -30.18% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $34.31 | -6.73% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $24.45 | -42.74% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $11.50
Upside: +4.35%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $11.19
Upside: +96.60%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.89
Upside: +534.92%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $100.22
Upside: -44.12%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $6.15
Upside: +257.72%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $37.24
Upside: -30.18%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $34.31
Upside: -6.73%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $24.45
Upside: -42.74%